UCB and Nodality Enter into a Multi-Year Strategic Collaboration
News Feb 10, 2012
UCB Pharma S.A. and Nodality, Inc. have announced a strategic collaboration utilizing Nodality’s proprietary Single Cell Network Profiling (SCNP) technology to assist the development of several UCB compounds.
The agreement establishes a multi-year collaborative investigation focusing initially on immunology disorders.
Based on information generated using Nodality’s technology, the agreement also gives UCB the option to engage Nodality to develop companion diagnostics for UCB’s compounds.
The terms of the agreement, whose details are not disclosed, include an upfront payment, R&D funding, and success-based milestones if all applicable development, regulatory and commercialization milestones are achieved.
In addition, Nodality may be eligible for royalties on future diagnostic sales.
David Parkinson, MD, Chief Executive Officer of Nodality, said, “We are delighted to be working together with UCB’s world class immunology research group to enhance their drug development activities. Based on Nodality’s extensive application of the SCNP platform to malignant and autoimmune diseases, we believe that we will be able to add significant value to UCB’s drug development portfolio. This collaboration is validation of Nodality’s unique technological approach and of the value the SCNP platform technology can bring to pharmaceutical drug development. We look forward to a close and productive working relationship with UCB’s research and development teams."
Ismail Kola, Executive Vice President and President, NewMedicines at UCB said, “We look forward to the Nodality collaboration as we advance UCB’s Research & Development pipeline. This collaboration represents a key component of UCB’s strategy to innovate on the paradigm of drug development through an enhanced understanding of disease pathways and drug mechanisms in order to realize the potential for patient stratification, targeted treatments and improved care for patients.”
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018